Side-by-side comparison of AI visibility scores, market position, and capabilities
NYC YC W23 DeFi mobile wallet making yield investing accessible via account abstraction; $31.3M total ($25M Lowercarbon Series A May 2025 + 2024 seed) with auto-compounding positions competing with Coinbase Wallet for mainstream DeFi adoption.
Rainmaker is a New York City-based DeFi mobile wallet — backed by Y Combinator (W23) with $31.3 million in total funding including a $25 million Series A in May 2025 from Lowercarbon Capital and others, following a 2024 seed from Starship Ventures, Long Journey Ventures, and Day One Ventures — providing mainstream users with an account-abstraction-based mobile crypto wallet that reduces the complexity of DeFi investing to a few taps, enabling auto-compounding yield positions with performance fees (similar to Beefy.finance) and planning subscription services and integrated tax reporting. Founded in 2023 and backed by Y Combinator W23, Rainmaker targets the mass market of potential DeFi participants who are deterred by wallet complexity, gas fee management, and protocol interaction barriers.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.